相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon
Jacob P. Laubach et al.
CLINICAL CANCER RESEARCH (2015)
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
Robert Z. Orlowski et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche
Valeria Quarona et al.
MARROW (2015)
The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting
T. Vaisitti et al.
LEUKEMIA (2015)
Current treatment landscape for relapsed and/or refractory multiple myeloma
Meletios A. Dimopoulos et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
Jesus San-Miguel et al.
BLOOD (2014)
Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma
Sheeba K. Thomas et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Jutta Deckert et al.
CLINICAL CANCER RESEARCH (2014)
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma
Francesca Donato et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Daratumumab granted breakthrough drug status
Jacob P. Laubach et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma
Jesus G. Berdeja
FRONTIERS IN BIOSCIENCE-LANDMARK (2014)
Multiple Myeloma in the Older Adult: Better Prospects, More Challenges
Tanya M. Wildes et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
D. Atanackovic et al.
LEUKEMIA (2014)
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
B. A. Walker et al.
LEUKEMIA (2014)
Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy
S. Gouard et al.
NUCLEAR MEDICINE AND BIOLOGY (2014)
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma
Jonathan L. Kaufman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
Peter M. Voorhees et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Shauna M. Collins et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
SAR650984: Characterization of a potent phase I humanized anti-CD38 antibody for the treatment of multiple myeloma and other hematologic malignancies.
Marie-Cecile Wetzel et al.
CANCER RESEARCH (2013)
Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma
Ruben Niesvizky et al.
CLINICAL CANCER RESEARCH (2013)
CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma
Andre Veillette et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma
Tyce J. Kearl et al.
JOURNAL OF IMMUNOLOGY (2013)
Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule
Antonella Chillemi et al.
MOLECULAR MEDICINE (2013)
Quality of Life and Supportive Care in Multiple Myeloma
Melda Comert et al.
TURKISH JOURNAL OF HEMATOLOGY (2013)
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Jeffrey A. Zonder et al.
BLOOD (2012)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
William Bensinger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Molecular pathogenesis of multiple myeloma and its premalignant precursor
W. Michael Kuehl et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
Andrzej J. Jakubowiak et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
S. K. Kumar et al.
LEUKEMIA (2012)
Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma
Maria-Victoria Mateos et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2012)
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
Don M. Benson et al.
BLOOD (2011)
Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
Sally A. Hunsucker et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma
Djordje Atanackovic et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies
M. S. van der Veer et al.
BLOOD CANCER JOURNAL (2011)
A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
Mohamad Hussein et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone
Maurizio Zangari et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death
Peter M. Voorhees et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
Hiroshi Ikeda et al.
CLINICAL CANCER RESEARCH (2009)
Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines
Rhona Stein et al.
CLINICAL CANCER RESEARCH (2009)
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
R. A. Kyle et al.
LEUKEMIA (2009)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu
Yu-Tzu Tai et al.
BLOOD (2008)
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
Eric D. Hsi et al.
CLINICAL CANCER RESEARCH (2008)
Prognostic value of immunophenotyping in multiple myeloma:: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy
Gema Mateo et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology
Fabio Malavasi et al.
PHYSIOLOGICAL REVIEWS (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma
Peter M. Voorhees et al.
CLINICAL CANCER RESEARCH (2007)
Neutralizing B-cell-activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined Immunodeficient human multiple myeloma model
Paola Neri et al.
CLINICAL CANCER RESEARCH (2007)
CD74: A new candidate target for the immunotherapy of B-Cell neoplasms
Rhona Stein et al.
CLINICAL CANCER RESEARCH (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
A Glasmacher et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
J Moreaux et al.
BLOOD (2004)
CD74 is expressed by multiple myeloma and is a promising target for therapy
JD Burton et al.
CLINICAL CANCER RESEARCH (2004)
Plasma cells: finding new light at the end of B cell development
KL Calame
NATURE IMMUNOLOGY (2001)
Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma:: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres
G Gahrton et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
